fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 36. More products

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Carvedilol

All strengths: Limited Use, Reason for Use code 183 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 183 required
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

Auro-Carvedilol · DIN 02418495 · 3.125 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Auro-Carvedilol · DIN 02418495 Manufacturer: Auro Pharma Inc.; listing date 2014-04-30 Daily cost (source): $0.4120 Health Canada: Marketed since 2014-02-06 · brand AURO-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02418495)

Source record
DIN 02418495: Auro-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id AUR Source form: Tab; strength: 3.125mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02418495 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90306
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060 Carvedilol · DIN 02248752 · $0.2060 Carvedilol · DIN 02364913 · $0.2060 Coreg · DIN 02229650 · not recorded Jamp-Carvedilol · DIN 02368897 · $0.2060 PMS-Carvedilol · DIN 02245914 · $0.2060 Ran-Carvedilol · DIN 02268027 · $0.2060 Ratio-Carvedilol · DIN 02252309 · $0.2060
Shortage status: resolved shortage (ended September 15, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02418495
Shortage record checked October 6, 2026

Carvedilol · DIN 02248752 · 3.125 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02248752 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-03-02 Daily cost (source): $0.4120 Health Canada: Marketed since 2018-10-24 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248752)

Source record
DIN 02248752: Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id SIV Source form: Tab; strength: 3.125mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248752 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73120
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060 Auro-Carvedilol · DIN 02418495 · $0.2060 Carvedilol · DIN 02364913 · $0.2060 Coreg · DIN 02229650 · not recorded Jamp-Carvedilol · DIN 02368897 · $0.2060 PMS-Carvedilol · DIN 02245914 · $0.2060 Ran-Carvedilol · DIN 02268027 · $0.2060 Ratio-Carvedilol · DIN 02252309 · $0.2060
Shortage status: resolved shortage (ended May 20, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248752
Shortage record checked October 6, 2026

Carvedilol · DIN 02364913 · 3.125 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02364913 Manufacturer: Sanis Health Inc.; listing date 2011-10-25 Daily cost (source): $0.4120 Health Canada: Marketed since 2013-10-12 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364913)

Source record
DIN 02364913: Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id SAI Source form: Tab; strength: 3.125mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364913 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84979
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060 Auro-Carvedilol · DIN 02418495 · $0.2060 Carvedilol · DIN 02248752 · $0.2060 Coreg · DIN 02229650 · not recorded Jamp-Carvedilol · DIN 02368897 · $0.2060 PMS-Carvedilol · DIN 02245914 · $0.2060 Ran-Carvedilol · DIN 02268027 · $0.2060 Ratio-Carvedilol · DIN 02252309 · $0.2060
Shortage status: resolved shortage (ended November 25, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02364913
Shortage record checked October 6, 2026

Jamp-Carvedilol · DIN 02368897 · 3.125 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Jamp-Carvedilol · DIN 02368897 Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27 Daily cost (source): $0.4120 Health Canada: Marketed since 2022-01-12 · brand JAMP-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02368897)

Source record
DIN 02368897: Jamp-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id JPC Source form: Tab; strength: 3.125mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02368897 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85386
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060 Auro-Carvedilol · DIN 02418495 · $0.2060 Carvedilol · DIN 02248752 · $0.2060 Carvedilol · DIN 02364913 · $0.2060 Coreg · DIN 02229650 · not recorded PMS-Carvedilol · DIN 02245914 · $0.2060 Ran-Carvedilol · DIN 02268027 · $0.2060 Ratio-Carvedilol · DIN 02252309 · $0.2060
Shortage status: resolved shortage (ended August 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02368897
Shortage record checked October 6, 2026

PMS-Carvedilol · DIN 02245914 · 3.125 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Carvedilol · DIN 02245914 Manufacturer: Pharmascience Inc.; listing date 2004-04-06 Daily cost (source): $0.4120 Health Canada: Marketed since 2003-08-04 · brand PMS-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245914)

Source record
DIN 02245914: PMS-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id PMS Source form: Tab; strength: 3.125mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245914 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70034
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060 Auro-Carvedilol · DIN 02418495 · $0.2060 Carvedilol · DIN 02248752 · $0.2060 Carvedilol · DIN 02364913 · $0.2060 Coreg · DIN 02229650 · not recorded Jamp-Carvedilol · DIN 02368897 · $0.2060 Ran-Carvedilol · DIN 02268027 · $0.2060 Ratio-Carvedilol · DIN 02252309 · $0.2060
Shortage status: resolved shortage (ended June 26, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245914
Shortage record checked October 6, 2026

Ratio-Carvedilol · DIN 02252309 · 3.125 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Carvedilol · DIN 02252309 Manufacturer: Ratiopharm Inc.; listing date 2004-07-20 Daily cost (source): $0.4120 Health Canada: Marketed since 2018-01-09 · brand TEVA-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ratio-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02252309)

Source record
DIN 02252309: Ratio-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id RPH Source form: Tab; strength: 3.125mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02252309 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73718
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060 Auro-Carvedilol · DIN 02418495 · $0.2060 Carvedilol · DIN 02248752 · $0.2060 Carvedilol · DIN 02364913 · $0.2060 Coreg · DIN 02229650 · not recorded Jamp-Carvedilol · DIN 02368897 · $0.2060 PMS-Carvedilol · DIN 02245914 · $0.2060 Ran-Carvedilol · DIN 02268027 · $0.2060
Shortage status: resolved shortage (ended May 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02252309
Shortage record checked October 6, 2026

Auro-Carvedilol · DIN 02418509 · 6.25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Auro-Carvedilol · DIN 02418509 Manufacturer: Auro Pharma Inc.; listing date 2014-04-30 Daily cost (source): $0.4120 Health Canada: Marketed since 2014-02-06 · brand AURO-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02418509)

Source record
DIN 02418509: Auro-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id AUR Source form: Tab; strength: 6.25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02418509 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90307
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060 Carvedilol · DIN 02248753 · $0.2060 Carvedilol · DIN 02364921 · $0.2060 Coreg · DIN 02229651 · not recorded Jamp-Carvedilol · DIN 02368900 · $0.2060 PMS-Carvedilol · DIN 02245915 · $0.2060 Ran-Carvedilol · DIN 02268035 · $0.2060 Ratio-Carvedilol · DIN 02252317 · $0.2060
Shortage status: resolved shortage (ended March 29, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02418509
Shortage record checked October 6, 2026

Carvedilol · DIN 02248753 · 6.25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02248753 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-03-02 Daily cost (source): $0.4120 Health Canada: Marketed since 2018-07-06 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248753)

Source record
DIN 02248753: Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id SIV Source form: Tab; strength: 6.25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248753 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73121
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060 Auro-Carvedilol · DIN 02418509 · $0.2060 Carvedilol · DIN 02364921 · $0.2060 Coreg · DIN 02229651 · not recorded Jamp-Carvedilol · DIN 02368900 · $0.2060 PMS-Carvedilol · DIN 02245915 · $0.2060 Ran-Carvedilol · DIN 02268035 · $0.2060 Ratio-Carvedilol · DIN 02252317 · $0.2060
Shortage status: resolved shortage (ended September 3, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248753
Shortage record checked October 6, 2026

Carvedilol · DIN 02364921 · 6.25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02364921 Manufacturer: Sanis Health Inc.; listing date 2011-10-25 Daily cost (source): $0.4120 Health Canada: Marketed since 2013-10-12 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364921)

Source record
DIN 02364921: Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id SAI Source form: Tab; strength: 6.25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364921 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84980
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060 Auro-Carvedilol · DIN 02418509 · $0.2060 Carvedilol · DIN 02248753 · $0.2060 Coreg · DIN 02229651 · not recorded Jamp-Carvedilol · DIN 02368900 · $0.2060 PMS-Carvedilol · DIN 02245915 · $0.2060 Ran-Carvedilol · DIN 02268035 · $0.2060 Ratio-Carvedilol · DIN 02252317 · $0.2060
Shortage status: resolved shortage (ended August 18, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02364921
Shortage record checked October 6, 2026

Jamp-Carvedilol · DIN 02368900 · 6.25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Jamp-Carvedilol · DIN 02368900 Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27 Daily cost (source): $0.4120 Health Canada: Marketed since 2022-01-12 · brand JAMP-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02368900)

Source record
DIN 02368900: Jamp-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id JPC Source form: Tab; strength: 6.25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02368900 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85387
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060 Auro-Carvedilol · DIN 02418509 · $0.2060 Carvedilol · DIN 02248753 · $0.2060 Carvedilol · DIN 02364921 · $0.2060 Coreg · DIN 02229651 · not recorded PMS-Carvedilol · DIN 02245915 · $0.2060 Ran-Carvedilol · DIN 02268035 · $0.2060 Ratio-Carvedilol · DIN 02252317 · $0.2060
Shortage status: resolved shortage (ended March 27, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02368900
Shortage record checked October 6, 2026

PMS-Carvedilol · DIN 02245915 · 6.25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Carvedilol · DIN 02245915 Manufacturer: Pharmascience Inc.; listing date 2004-04-06 Daily cost (source): $0.4120 Health Canada: Marketed since 2003-08-04 · brand PMS-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245915)

Source record
DIN 02245915: PMS-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id PMS Source form: Tab; strength: 6.25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245915 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70035
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060 Auro-Carvedilol · DIN 02418509 · $0.2060 Carvedilol · DIN 02248753 · $0.2060 Carvedilol · DIN 02364921 · $0.2060 Coreg · DIN 02229651 · not recorded Jamp-Carvedilol · DIN 02368900 · $0.2060 Ran-Carvedilol · DIN 02268035 · $0.2060 Ratio-Carvedilol · DIN 02252317 · $0.2060
Shortage status: resolved shortage (ended June 26, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245915
Shortage record checked October 6, 2026

Ratio-Carvedilol · DIN 02252317 · 6.25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Carvedilol · DIN 02252317 Manufacturer: Ratiopharm Inc.; listing date 2004-07-20 Daily cost (source): $0.4120 Health Canada: Marketed since 2018-01-09 · brand TEVA-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ratio-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02252317)

Source record
DIN 02252317: Ratio-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id RPH Source form: Tab; strength: 6.25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02252317 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73719
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060 Auro-Carvedilol · DIN 02418509 · $0.2060 Carvedilol · DIN 02248753 · $0.2060 Carvedilol · DIN 02364921 · $0.2060 Coreg · DIN 02229651 · not recorded Jamp-Carvedilol · DIN 02368900 · $0.2060 PMS-Carvedilol · DIN 02245915 · $0.2060 Ran-Carvedilol · DIN 02268035 · $0.2060
Shortage status: resolved shortage (ended May 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02252317
Shortage record checked October 6, 2026

Auro-Carvedilol · DIN 02418517 · 12.5 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Auro-Carvedilol · DIN 02418517 Manufacturer: Auro Pharma Inc.; listing date 2014-04-30 Daily cost (source): $0.4120 Health Canada: Marketed since 2014-02-06 · brand AURO-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02418517)

Source record
DIN 02418517: Auro-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id AUR Source form: Tab; strength: 12.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02418517 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90308
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060 Carvedilol · DIN 02248754 · $0.2060 Carvedilol · DIN 02364948 · $0.2060 Coreg · DIN 02229652 · not recorded Jamp-Carvedilol · DIN 02368919 · $0.2060 PMS-Carvedilol · DIN 02245916 · $0.2060 Ran-Carvedilol · DIN 02268043 · $0.2060 Ratio-Carvedilol · DIN 02252325 · $0.2060
Shortage status: resolved shortage (ended October 28, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02418517
Shortage record checked October 6, 2026

Carvedilol · DIN 02248754 · 12.5 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02248754 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-03-02 Daily cost (source): $0.4120 Health Canada: Marketed since 2018-07-06 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248754)

Source record
DIN 02248754: Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id SIV Source form: Tab; strength: 12.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248754 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73122
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060 Auro-Carvedilol · DIN 02418517 · $0.2060 Carvedilol · DIN 02364948 · $0.2060 Coreg · DIN 02229652 · not recorded Jamp-Carvedilol · DIN 02368919 · $0.2060 PMS-Carvedilol · DIN 02245916 · $0.2060 Ran-Carvedilol · DIN 02268043 · $0.2060 Ratio-Carvedilol · DIN 02252325 · $0.2060
Shortage status: resolved shortage (ended August 12, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248754
Shortage record checked October 6, 2026

Carvedilol · DIN 02364948 · 12.5 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02364948 Manufacturer: Sanis Health Inc.; listing date 2011-10-25 Daily cost (source): $0.4120 Health Canada: Marketed since 2013-10-12 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364948)

Source record
DIN 02364948: Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id SAI Source form: Tab; strength: 12.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364948 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84981
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060 Auro-Carvedilol · DIN 02418517 · $0.2060 Carvedilol · DIN 02248754 · $0.2060 Coreg · DIN 02229652 · not recorded Jamp-Carvedilol · DIN 02368919 · $0.2060 PMS-Carvedilol · DIN 02245916 · $0.2060 Ran-Carvedilol · DIN 02268043 · $0.2060 Ratio-Carvedilol · DIN 02252325 · $0.2060
Shortage status: resolved shortage (ended April 22, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02364948
Shortage record checked October 6, 2026

Jamp-Carvedilol · DIN 02368919 · 12.5 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Jamp-Carvedilol · DIN 02368919 Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27 Daily cost (source): $0.4120 Health Canada: Marketed since 2022-01-12 · brand JAMP-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02368919)

Source record
DIN 02368919: Jamp-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id JPC Source form: Tab; strength: 12.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02368919 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85388
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060 Auro-Carvedilol · DIN 02418517 · $0.2060 Carvedilol · DIN 02248754 · $0.2060 Carvedilol · DIN 02364948 · $0.2060 Coreg · DIN 02229652 · not recorded PMS-Carvedilol · DIN 02245916 · $0.2060 Ran-Carvedilol · DIN 02268043 · $0.2060 Ratio-Carvedilol · DIN 02252325 · $0.2060
Shortage status: resolved shortage (ended July 13, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02368919
Shortage record checked October 6, 2026

PMS-Carvedilol · DIN 02245916 · 12.5 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Carvedilol · DIN 02245916 Manufacturer: Pharmascience Inc.; listing date 2004-04-06 Daily cost (source): $0.4120 Health Canada: Marketed since 2003-08-04 · brand PMS-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245916)

Source record
DIN 02245916: PMS-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id PMS Source form: Tab; strength: 12.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245916 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70036
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060 Auro-Carvedilol · DIN 02418517 · $0.2060 Carvedilol · DIN 02248754 · $0.2060 Carvedilol · DIN 02364948 · $0.2060 Coreg · DIN 02229652 · not recorded Jamp-Carvedilol · DIN 02368919 · $0.2060 Ran-Carvedilol · DIN 02268043 · $0.2060 Ratio-Carvedilol · DIN 02252325 · $0.2060
Shortage status: resolved shortage (ended July 12, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245916
Shortage record checked October 6, 2026

Ratio-Carvedilol · DIN 02252325 · 12.5 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Carvedilol · DIN 02252325 Manufacturer: Ratiopharm Inc.; listing date 2004-07-20 Daily cost (source): $0.4120 Health Canada: Marketed since 2018-01-09 · brand TEVA-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ratio-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02252325)

Source record
DIN 02252325: Ratio-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id RPH Source form: Tab; strength: 12.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02252325 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73720
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060 Auro-Carvedilol · DIN 02418517 · $0.2060 Carvedilol · DIN 02248754 · $0.2060 Carvedilol · DIN 02364948 · $0.2060 Coreg · DIN 02229652 · not recorded Jamp-Carvedilol · DIN 02368919 · $0.2060 PMS-Carvedilol · DIN 02245916 · $0.2060 Ran-Carvedilol · DIN 02268043 · $0.2060
Shortage status: resolved shortage (ended May 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02252325
Shortage record checked October 6, 2026

Auro-Carvedilol · DIN 02418525 · 25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Auro-Carvedilol · DIN 02418525 Manufacturer: Auro Pharma Inc.; listing date 2014-04-30 Daily cost (source): $0.4120 Health Canada: Marketed since 2014-02-06 · brand AURO-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02418525)

Source record
DIN 02418525: Auro-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id AUR Source form: Tab; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02418525 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90309
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060 Carvedilol · DIN 02248755 · $0.2060 Carvedilol · DIN 02364956 · $0.2060 Coreg · DIN 02229653 · not recorded Jamp-Carvedilol · DIN 02368927 · $0.2060 PMS-Carvedilol · DIN 02245917 · $0.2060 Ran-Carvedilol · DIN 02268051 · $0.2060 Ratio-Carvedilol · DIN 02252333 · $0.2060
Shortage status: resolved shortage (ended October 28, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02418525
Shortage record checked October 6, 2026

Carvedilol · DIN 02248755 · 25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02248755 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-03-02 Daily cost (source): $0.4120 Health Canada: Marketed since 2018-07-06 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248755)

Source record
DIN 02248755: Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id SIV Source form: Tab; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248755 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73123
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060 Auro-Carvedilol · DIN 02418525 · $0.2060 Carvedilol · DIN 02364956 · $0.2060 Coreg · DIN 02229653 · not recorded Jamp-Carvedilol · DIN 02368927 · $0.2060 PMS-Carvedilol · DIN 02245917 · $0.2060 Ran-Carvedilol · DIN 02268051 · $0.2060 Ratio-Carvedilol · DIN 02252333 · $0.2060
Shortage status: resolved shortage (ended September 3, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248755
Shortage record checked October 6, 2026

Carvedilol · DIN 02364956 · 25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02364956 Manufacturer: Sanis Health Inc.; listing date 2011-10-25 Daily cost (source): $0.4120 Health Canada: Marketed since 2013-10-12 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364956)

Source record
DIN 02364956: Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id SAI Source form: Tab; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364956 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84982
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060 Auro-Carvedilol · DIN 02418525 · $0.2060 Carvedilol · DIN 02248755 · $0.2060 Coreg · DIN 02229653 · not recorded Jamp-Carvedilol · DIN 02368927 · $0.2060 PMS-Carvedilol · DIN 02245917 · $0.2060 Ran-Carvedilol · DIN 02268051 · $0.2060 Ratio-Carvedilol · DIN 02252333 · $0.2060
Shortage status: resolved shortage (ended October 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02364956
Shortage record checked October 6, 2026

Jamp-Carvedilol · DIN 02368927 · 25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Jamp-Carvedilol · DIN 02368927 Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27 Daily cost (source): $0.4120 Health Canada: Marketed since 2022-01-12 · brand JAMP-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02368927)

Source record
DIN 02368927: Jamp-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id JPC Source form: Tab; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02368927 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85389
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060 Auro-Carvedilol · DIN 02418525 · $0.2060 Carvedilol · DIN 02248755 · $0.2060 Carvedilol · DIN 02364956 · $0.2060 Coreg · DIN 02229653 · not recorded PMS-Carvedilol · DIN 02245917 · $0.2060 Ran-Carvedilol · DIN 02268051 · $0.2060 Ratio-Carvedilol · DIN 02252333 · $0.2060
Shortage status: resolved shortage (ended July 13, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02368927
Shortage record checked October 6, 2026

PMS-Carvedilol · DIN 02245917 · 25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Carvedilol · DIN 02245917 Manufacturer: Pharmascience Inc.; listing date 2004-04-06 Daily cost (source): $0.4120 Health Canada: Marketed since 2003-08-04 · brand PMS-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245917)

Source record
DIN 02245917: PMS-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id PMS Source form: Tab; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245917 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70037
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060 Auro-Carvedilol · DIN 02418525 · $0.2060 Carvedilol · DIN 02248755 · $0.2060 Carvedilol · DIN 02364956 · $0.2060 Coreg · DIN 02229653 · not recorded Jamp-Carvedilol · DIN 02368927 · $0.2060 Ran-Carvedilol · DIN 02268051 · $0.2060 Ratio-Carvedilol · DIN 02252333 · $0.2060
Shortage status: resolved shortage (ended September 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245917
Shortage record checked October 6, 2026

Ratio-Carvedilol · DIN 02252333 · 25 mg · tablet

Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit: For patients with: Reason for Use code 183 a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Carvedilol · DIN 02252333 Manufacturer: Ratiopharm Inc.; listing date 2004-07-20 Daily cost (source): $0.4120 Health Canada: Marketed since 2018-01-09 · brand TEVA-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ratio-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.

Ministry pays: $0.2060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02252333)

Source record
DIN 02252333: Ratio-Carvedilol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id RPH Source form: Tab; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2060; ministry $0.2060 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02252333 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73721
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060 Auro-Carvedilol · DIN 02418525 · $0.2060 Carvedilol · DIN 02248755 · $0.2060 Carvedilol · DIN 02364956 · $0.2060 Coreg · DIN 02229653 · not recorded Jamp-Carvedilol · DIN 02368927 · $0.2060 PMS-Carvedilol · DIN 02245917 · $0.2060 Ran-Carvedilol · DIN 02268051 · $0.2060
Shortage status: resolved shortage (ended October 1, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02252333
Shortage record checked October 6, 2026

Other products in the same Health Canada class (C07A): coverage varies; not interchangeable

  • Acebutolol (Sectral): general benefit, not a benefit
  • Atenolol (Apo-Atenol): general benefit
  • Bisoprolol (Sandoz Bisoprolol Tablets): general benefit, not a benefit
  • Metoprolol (Lopresor SR): general benefit, not a benefit
  • Nadolol (Corgard): general benefit, not a benefit
  • Propranolol (Inderal-LA): general benefit, not a benefit

3 more in the class list below

Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00 24:04 Cardiac Drugs

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

NADOLOL

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 40mg, 80mg, 160mg · Tab

PROPRANOLOL

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (8), General benefit (7), Listed, not a benefit (4) · strengths: 60mg, 80mg, 120mg, 160mg, 10mg, 20mg, 40mg · LA Cap, Tab

SOTALOL HCL

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 80mg, 160mg · Tab

TIMOLOL MALEATE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

NEBIVOLOL HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 59 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS pms-CARVEDILOL (carvedilol) is indicated:  for the treatment of mild, moderate or severe heart failure of ischemic or non-ischemic origin to increase survival and also, to reduce the combined risk of all-cause mortality and cardiovascular or non-cardiovascular hospitalizations In general, pms-CARVEDILOL is used in conjunction with diuretics and an ACE inhibitor, with or without digitalis. pms-CARVEDILOL should be prescribed by a Health professional experienced in the treatment of heart failure. 1.1 Pediatrics Pediatrics (under 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (over 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00065327.PDF PM date: April 4, 2022 Source product: PMS-CARVEDILOL; DIN 02245914; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.